A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis
Latest Information Update: 09 Jun 2021
At a glance
- Drugs Opicinumab (Primary)
- Indications Optic neuritis
- Focus Therapeutic Use
- Acronyms RENEW
- Sponsors Biogen
- 22 Apr 2021 Results of A Post Hoc Analysis of RENEW and RENEWED presented at the 73rd Annual Meeting of the American Academy of Neurology
- 28 Sep 2018 Results of exploratory MF-VEP RENEW substudy published in the CNS Drugs.
- 28 Oct 2017 Results assessing optimal thresholds for inter-eye difference in RNFL thickness for predicting a unilateral optic nerve lesion, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis